Podcast appearances and mentions of Leonard H Calabrese

On this episode, hear the 2024 updates on COVID-19, long COVID and the latest developments in research in rheumatology. Hosted by Dr. Leonard Calabrese. Intro 0:12 In this episode 0:21 Coming up on Healio Rheuminations 0:56 COVID-19, long COVID and the rheumatologist with Leonard Calabrese, DO 2:19 Questions 3:12 Long COVID 4:46 Calabrese's bias 10:15 The evidence 13:08 Auto antibodies 14:54 Why does the body develop auto antibodies? 17:47 COVID-19 and epidemiologic association 22:25 New clinical entity 26:40 Therapeutic implications 31:00 In conclusion 32:00 Thanks for listening 33:18 Leonard H. Calabrese, DO, is the chief medical editor, Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic. Disclosures: Calabrese reports professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

What should rheumatologists know about what we've learned about COVID-19 and long COVID in 2023? Hosted by Dr. Leonard Calabrese. ·       Intro 0:11 ·       In this episode 0:21 ·       2023: current status and controversies 0:35 ·       What is going on with COVID-19? 01:53 ·       What do we know about vaccine responses? What should we be telling our patients about vaccines in our immunocompromised population? 2:58 ·       Lancet Rheumatology MELODY study summary 3:08 ·       What about patients within the rheumatic and autoimmune disease space? 4:15 ·       Who is immunocompromised and why does it matter? 5:11 ·       What is the immunosuppression we are giving them? 6:39 ·       What to tell patients about getting vaccinated 8:56 ·       Long COVID 10:09 ·       What is long COVID? 10:26 ·       JAMA Network Open study on prevalence and characteristics associated with post-COVID conditions 14:19 ·       In the clinical arena, what should rheumatologists be thinking about? 16:38 ·       What about pathogenesis? What do we know about the controversies in this area? 18:58 ·       Autoimmunity: COVID-19 and autoimmune response 20:45 ·       What about therapies? 22:22 ·       The next generation of rheum agents: Immunomodulation with neonatal Fc receptor targeting? 24:40 ·       A question for the rheumatology community: do patients with immune mediated diseases get more long COVID than the control population? 25:40 ·       In conclusion 27:37 ·       Thanks for listening 28:38 Leonard H. Calabrese, DO, is the chief medical editor, Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic. Disclosures: Calabrese reports professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB.. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

In this episode of Meeting Mic, we bring you Healio's top headlines from ACR Convergence 2023.  Eric Roberts, PhD, MPH, compares the uptake of biosimilar infliximab among patients with Medicare, Medicaid and private insurance in the U.S. :19  Shivani Garg, MD, MS, discusses how a therapeutic range of hydroxychloroquine blood levels may reduce the odds of high lupus disease activity. 2:09  Kaleb Michaud, PhD, discusses patients with rheumatoid arthritis who reported having long COVID in the past year demonstrating “many symptoms” of long COVID prior to initial infection. 12:00  Leonard H. Calabrese, DO, highlights the “year in review”, issues in vasculitis, and cautionary notes on CAR T cell therapies. 14:18   Jill Buyon, MD, discusses how pregnant patients with very low anti-Ro antibody titers of less than 1,000 units per mL have minimal-to-no risk for fetal atrioventricular block. 15:15  Read the full coverage here:  https://www.healio.com/news/rheumatology/20231113/medicare-fails-to-keep-up-with-medicaid-private-market-on-infliximab-biosimilar-uptake  https://www.healio.com/news/rheumatology/20231120/stay-within-hydroxychloroquine-therapeutic-threshold-to-reduce-active-lupus-flare-risk   https://www.healio.com/news/rheumatology/20231116/patients-with-rheumatoid-arthritis-report-many-symptoms-of-long-covid-prior-to-infection   @LCalabreseDO  https://www.healio.com/news/rheumatology/20231113/pregnant-patients-with-low-antiro-titers-have-little-to-no-risk-for-fetal-heart-block  Disclosures:  Roberts, Garg, Michaud and Calabrese report no relevant financial disclosures. Buyon reports financial disclosures with Bristol-Myers Squibb, GlaxoSmithKline and Related Sciences. 

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

In this episode, Joel M. Gelfand, MD, MSCE, is joined by Leonard H. Calabrese, DO, and Amesh Adalja, MD, FIDSA, as they discuss quarantine and isolation guidelines, emerging therapies to treat COVID-19, and the anticipated future of the COVID-19 pandemic. Welcome from Joel Gelfand, MD, MSCE :10 About Calabrese and Adalja :11 At day five, what's your recommendation for clinicians how to counsel people about testing to get out of isolation? Do you recommend people go ahead and get tested to end isolation or to just end isolation if not having much symptoms or improving? :51 How should we counsel our immunocompromised patients? Should they really isolate for 20 days? 5:21 Can people continue to test positive and antigen test beyond the infectious period? 10:13 In the clinical setting, you know, should physicians be wearing N95 masks, and if so, what's that databased on? 15:22 If a person has a positive antigen test but a negative PCR on the same day, how do you interpret that information for a patient? 22:12 Now we finally have emergence of effective therapies for people with COVID-19. How do you think about these different therapies? Do you have an algorithm that you'd recommend to clinicians in the field about which one to reach for first? 24:05 When someone has a COVID infection how soon thereafter can you give them a COVID immunization? 27:47 With Omicron working its way through the US and obviously through the world, where do you see the next three to six months going? 28:34 Thank you everyone 31:29 Amesh Adalja, MD, FIDSA,is senior scholar at Johns Hopkins and a practicing infectious disease and critical care physician in Pittsburgh. Leonard H. Calabrese, DO, is chief medical editor of Healio Rheumatology, professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer Chair of Clinical Immunology at the Cleveland Clinic. Joel M. Gelfand, MD, MSCE, is chief medical editor of Healio Psoriatic Disease and professor of dermatology and epidemiology at the Perelman School of Medicine at the University of Pennsylvania. He is also vice chair of clinical research, medical director at the Dermatology Clinical Studies Unit, and director of the Psoriasis and Phototherapy Treatment Center at Penn Medicine. We'd love to hear from you! Send your comments/questions to Dr. Gelfand, Calabrese and Adalja at covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews, @GoHealio, @DrJoelGelfand, @LCalabreseDO and @AmeshAA. Disclosures: Adalja reports no relevant financial disclosures. Calabrese reports consulting for AstraZeneca, GSK and Regeneron. Gelfand reports serving as a consultant for Abcentra, Abbvie, BMS, Boehringer Ingelheim, GSK, Lilly (DMC), Janssen Biologics, Novartis Corp, UCB (DSMB), Neuroderm (DSMB), Trevi, and Mindera Dx., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Boehringer Ingelheim, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly pharmaceutical sponsors. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma. Gelfand is a deputy editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology, is chief medical editor for Healio Psoriatic Disease (receiving honoraria) and is a member of the Board of Directors for the International Psoriasis Council, receiving no honoraria.

In this episode, Joel M. Gelfand, MD, MSCE, and Leonard H. Calabrese, DO, are joined by Paul E. Sax, MD, as they discuss advances in the outpatient management of COVID-19 and emerging information about the omicron variant. Welcome from Joel Gelfand, MD, MSCE :10 About Calabrese, Gelfand and Sax :25 A quick update since the last webinar :51 Sax's thoughts on the effectiveness of monoclonal antibodies 1:46 What are the situations where we should be thinking about postexposure prophylaxis with these agents? 7:06 When you start using pre-exposure prophylaxis therapy, how would you counsel the patients receiving it? 12:56 How does Merck's molnupiravir work? 17:22 Sax's thoughts on Pfizer's paxlovid 22:23 What's your perspective on fluvoxamine? Does it work? 25:26 Paul, what have you learned so far about the omicron variant? 30:15 How much more contagious is this than Delta and what would you compare it to? 31:09 Questions from the audience 35:27 Tweet your questions @DrJoelGelfand, @LCalabreseDO and @PaulSaxMD. 38:35 Leonard H. Calabrese, DO, is chief medical editor of Healio Rheumatology, professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer Chair of Clinical Immunology at the Cleveland Clinic. Joel M. Gelfand, MD, MSCE, is chief medical editor of Healio Psoriatic Disease and professor of dermatology and epidemiology at the Perelman School of Medicine at the University of Pennsylvania. He is also vice chair of clinical research, medical director at the Dermatology Clinical Studies Unit, and director of the Psoriasis and Phototherapy Treatment Center at Penn Medicine. Paul E. Sax, MD, is clinical director of the Infectious Disease Clinic and professor of medicine at Harvard Medical School. We'd love to hear from you! Send your comments/questions to Drs. Gelfand, Calabrese and Sax at covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews, @GoHealio, @DrJoelGelfand, @LCalabreseDO and @PaulSaxMD. Disclosures: Calabrese reports consulting for AstraZeneca, GSK and Regeneron. Gelfand and Sax report no relevant financial disclosures. 

Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

Go online to PeerView.com/ZHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatic diseases discusses strategies to select and optimize treatment for individual patients with RA and PsA, focusing on the appropriate clinical utilization of newer treatment options (ie, JAK inhibitors). Upon completion of this activity, participants will be able to: Outline advances that have improved the quality of care in rheumatic diseases, Explain the role of the JAK/STAT signaling pathway in the pathophysiology of RA and PsA, Summarize efficacy and safety data related to current JAK inhibitors for the treatment of RA and PsA, Treat RA and PsA in accordance with current evidence and guidelines, recognizing the role of non-anti-TNF therapies in patients with active disease, Incorporate JAK inhibitors into treatment plans for individual patients with RA or PsA, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.

In this episode, Leonard H. Calabrese, DO, is joined by his colleague and daughter Cassandra Calabrese, DO, as they discuss specifics of irAEs, including unusual toxicities, rheumatic conditions associated with checkpoint inhibitors and the rheumatologist’s role in this new area of medicine. Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com. Intro :22 Recap of Part 1 :40 An interview with Cassandra Calabrese, DO 2:02 The number of patients with irAEs will grow 2:22 How many people actually experience irAEs? 3:40 Any examples of unusual toxicities? 5:49 What’s the timeline? 6:51 Have you seen patients with delayed onset? 8:10 Most of our patients have had one irAE or another beforehand 9:04 Who’s the captain of this ship? 10:15 What about inflammatory arthritis? 10:55 What about polymyalgia rheumatica? 13:48 Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com What about sicca, is it Sjogren’s? 16:22 Can you tell us about myositis in this context? 18:38 An overview of the guidelines 21:47 Check out our article in March Current Opinions in Rheumatology 24:12 What about patients with preexisting autoimmunity? 24:33 Are you worried about blunting tumor response? 27:10 Are there any biomarkers to predict this? 28:30 How have you been working with oncologists to manage/educate? 29:42 What about meetings? 31:04 Rheumatologists have a special place in this new area of medicine 31:45 We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum @LCalabreseDO @CCalabreseDO Disclosure: Brown and Cassandra Calabrese report no relevant financial disclosures. Leonard Calabrese reports serving as an investigator and a consultant to Horizon Pharmaceuticals. Cassandra Calabrese, DO, is associate staff member in the department of rheumatic and immunologic disease and department of infectious disease at the Cleveland Clinic. Leonard H. Calabrese, DO, is chief medical editor of Healio Rheumatology and director of the RJ Fasenmyer Center for Clinical Immunology at the Cleveland Clinic.

Checkpoint inhibitors have changed the field of oncology, as well as our understanding of autoimmunity. This episode, hosted by Leonard H. Calabrese, DO, walks us through the history of checkpoint inhibitors — from Dr. William Coley’s use of infections in cancer to the development of PD-1 inhibitors. Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com Intro :20 In this episode with Dr. Calabrese 3:07 Book recommendations 4:28 Harnessing the power of the immune system to fight cancer 5:33 William Coley and a patient 6:30 The search for Fred Stein 11:40 Coley designs an experiment 13:09 A different strain of streptococcus 16:16 The beginning of cancer therapy and immunotherapy 19:18 Where do we go from there? 20:49 Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com. What about tumor immunology? 21:55 The breakthrough 24:01 What do immunology and checkpoints have to do with it? 26:47 What happens when the danger signal cannot be dispatched? 34:02 Why do we, as rheumatologists, care about this? 36:04 CHAI and LATTE 38:49 Check out some papers on immunopathogenesis of irAEs 40:56 Checkpoint inhibitors for autoimmune diseases; RA and GCA 41:41 Come back for part 2 43:00 We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum @LCalabreseDO Disclosures: Brown reports no relevant financial disclosures. Calabrese reports serving as an investigator and a consultant to Horizon Pharmaceuticals. Leonard H. Calabrese, DO, is chief medical editor of Healio Rheumatology and director of the RJ Fasenmyer Center for Clinical Immunology at the Cleveland Clinic.

In this case-based podcast, Leonard H. Calabrese, DO, and Adam Brown, MD, discuss a patient presenting for a second opinion for GCA after initial workup and treatment by her primary care physician.

In this case-based podcast, Leonard H. Calabrese, DO, and Ann P. Murchison, MD, MPH, discuss issues related to the workup, diagnosis, and treatment of a patient with new-onset visual symptoms presenting to the emergency department.

In this case-based podcast, Leonard H. Calabrese, DO, and Adam Brown, MD, discuss a patient who presents to the hospital with fever of unknown origin.

In this case-based podcast, Leonard H. Calabrese, DO, and Sebastian Unizony, MD, discuss issues related to the workup, diagnosis, and treatment of a patient with complicated GCA.

In this case-based podcast, Leonard H. Calabrese, DO, and Sebastian Unizony, MD, discuss issues related to the workup, diagnosis, and treatment of a patient with uncomplicated, or “classic”, GCA.

In this MedEdTalks Micro-CE podcast, Leonard H. Calabrese, DO, and John H. Stone, MD, MPH, discuss management strategies for Giant Cell Arteritis (GCA).  

In this MedEdTalks Micro-CE podcast, Leonard H. Calabrese, DO, and John H. Stone, MD, MPH, discuss the diagnosis and natural history of Giant Cell Arteritis (GCA). 

Immunology is connected to every organ system in the body... your heart, your brain, your digestive system, and more.Your immune system is critical for defending yourself against bacteria and viruses.But, it's also important also in other health areas. Immunology is connected to every organ system in the body... your heart, your brain, your digestive system, and more.Leonard H. Calabrese, DO, heads Cleveland Clinic's Section of Clinical Immunology and manages its Clinical Immunology Clinic. He joins Dr. Roizen to discuss all the intricacies of the immune system and why you need to keep yours healthy to live a long, healthy life.BonusThe Perfect 70-Calorie Snack

Go online to PeerView.com/DEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses strategies to adequately identify and manage individuals with axSpA in the primary care setting. Upon completion of this activity, participants should be better able to: Identify axial spondyloarthritis (axSpA) in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Apply classification criteria and diagnostic tests into clinical practice to support early detection of axSpA, Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ a collaborative, multidisciplinary approach to ensure optimal treatment and long-term overall management of individual patients with axSpA.

Go online to PeerView.com/DEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses strategies to adequately identify and manage individuals with axSpA in the primary care setting. Upon completion of this activity, participants should be better able to: Identify axial spondyloarthritis (axSpA) in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Apply classification criteria and diagnostic tests into clinical practice to support early detection of axSpA, Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ a collaborative, multidisciplinary approach to ensure optimal treatment and long-term overall management of individual patients with axSpA.

Go online to PeerView.com/DEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses strategies to adequately identify and manage individuals with axSpA in the primary care setting. Upon completion of this activity, participants should be better able to: Identify axial spondyloarthritis (axSpA) in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Apply classification criteria and diagnostic tests into clinical practice to support early detection of axSpA, Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ a collaborative, multidisciplinary approach to ensure optimal treatment and long-term overall management of individual patients with axSpA.

Go online to PeerView.com/DEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses strategies to adequately identify and manage individuals with axSpA in the primary care setting. Upon completion of this activity, participants should be better able to: Identify axial spondyloarthritis (axSpA) in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Apply classification criteria and diagnostic tests into clinical practice to support early detection of axSpA, Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ a collaborative, multidisciplinary approach to ensure optimal treatment and long-term overall management of individual patients with axSpA.

Go online to PeerView.com/DEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses strategies to adequately identify and manage individuals with axSpA in the primary care setting. Upon completion of this activity, participants should be better able to: Identify axial spondyloarthritis (axSpA) in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Apply classification criteria and diagnostic tests into clinical practice to support early detection of axSpA, Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ a collaborative, multidisciplinary approach to ensure optimal treatment and long-term overall management of individual patients with axSpA.

Go online to PeerView.com/DEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses strategies to adequately identify and manage individuals with axSpA in the primary care setting. Upon completion of this activity, participants should be better able to: Identify axial spondyloarthritis (axSpA) in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Apply classification criteria and diagnostic tests into clinical practice to support early detection of axSpA, Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ a collaborative, multidisciplinary approach to ensure optimal treatment and long-term overall management of individual patients with axSpA.

Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they're used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.

Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they're used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.

Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they're used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.

Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they're used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.

Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they're used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.

Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they're used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.

Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they're used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.

Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they're used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs. They also discuss how rheumatologists and oncologists can effectively collaborate to determine if patients with cancer (eg, those with pre-existing autoimmune conditions) can safely receive and benefit from immune checkpoint inhibitor therapy, as well as to evaluate and manage rheumatic irAEs in patients who have developed them as a result of treatment with cancer immunotherapies. Upon completion of this activity, participants will be able to: Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse events (irAEs) associated with immunotherapies, Assess the potential benefits and risks of cancer immunotherapies for patients with cancer who have pre-existing autoimmune conditions to determine candidacy for cancer immunotherapy, Describe the spectrum of rheumatic and other irAEs associated with the immune checkpoint inhibitors, including incidence and presentation, Discuss the general and organ/site-specific recommendations for evaluation, diagnosis, grading, and management of irAEs, including the more and less commonly occurring rheumatic irAEs, Evaluate whether or not cancer immunotherapies can be safely considered for patients with cancer who have concomitant autoimmune conditions, based on individualized assessment of risks and benefits in collaboration with oncology, Implement recommended strategies for triage, evaluation, diagnosis, and management of rheumatic and other relevant irAEs in rheumatology practice in collaboration with oncology.

Guest: Leonard H. Calabrese, DO Guest: John R. Tesser, MD This activity provides patient and practice-specific biosimilars content for clinicians in rheumatology practice.